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Objective: We aimed to evaluate expression levels of nine candidate surface markers for chondrogenic
potential in human synovial cells and to determine whether cell pellets positively sorted by each speciﬁc
marker would have valuable chondrogenic potential.
Methods: The expression levels of the selected nine leading surface markers in synovial cells from knee
joints in 15 patients with primary knee osteoarthritis were evaluated at the stage of isolation and after
cultivation using ﬂow cytometry. We obtained positive and negative cells for each surface marker using
a magnetically activated cell sorting method and compared chondrogenic potentials between the posi-
tive and the negative cell pellets.
Results: CD29, CD44, CD73, and CD90 were expressed on the most synovial cells at the isolation stage and
on almost all cells at stage of P0 and P1. CD133 was rarely expressed at any stages of the evaluated cells.
CD166 was expressed in 7.1% of cells at the isolation stage on average, but this expression increased after
cell passages. The expressions of CD10 and CD105 also increased after cell passages while the expression
of CD49a made no signiﬁcant difference at progressive stages of isolation and passage. Comparison of
chondrogenic potentials between positive and negative cell pellets for each marker revealed that only
CD105- and CD166-positive cell pellets showed better chondrogenic potentials (type II collagen gene
expression, cartilage matrix formation, and GAG expression) than the corresponding negative cell pellets.
Conclusion: Our study suggests that CD105 and CD166 would be valuable surface markers associated with
chondrogenic potential; thus, CD105- and CD166-enriched cells derived from human synoviumwould be
practical and valuable sources for cartilage regeneration.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage is a dense, avascular, aneural tissue and thus
has a very limited healing capacity when impaired by trauma or
osteoarthritis (OA)1e3. Several surgical treatments, such as micro-
fracture, osteochondral graft transfers (autografts and allografts),
and autologous chondrocyte implantation, have been introduced
with some clinical success1,4. However, these procedures have
limitations, such as production of ﬁbrocartilage, donor site
morbidity, limited availability of grafts, and the limited expansion
capacity of chondrocytes3,5. As a solution to overcome theseo: M.C. Lee, Department of
ge of Medicine, #28 Yongon-
82-2-2072-3212; Fax: 82-2-
s Research Society International. Plimitations, use of stem cells and in particular, mesenchymal stem
cells (MSCs) from adult sources, has received recent attention6e8.
Adult MSCs are easily isolated, rapidly expanded, and have the
proven capability of both self-renewal and speciﬁc-lineage differ-
entiation. Adult MSCs are also free from ethical problems and
immune-related problems related to the use of embryonic stem
cells. These multipotent cells had been documented in several
tissues, including bone marrow9, skeletal muscle10, neural tissue11,
adipose tissue12, and synovium13.
Among various sources, synovium is the tissue located closest to
articular cartilage and is easily harvested with negligible donor site
morbidity during arthroscopic surgery. Since Hunziker et al. re-
ported evidence that cells recruited from synovium have an
important role in the repair of damaged cartilage14, several reports
demonstrated that synovium-derived MSCs possess valuable
proliferative capacity and multi-differentiation potential13e16,
speciﬁcally with respect to chondrogenic differentiation.
However, without regard to the source of cells, adult MSCs have
critical limitations in their clinical applications, includingublished by Elsevier Ltd. All rights reserved.
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multipotent cells among the harvested cells. One of the potential
solutions for these problems is performing isolation of MSCs using
speciﬁc markers (cell surface antigens) that represent multi-
potentiality. For bone marrow cells, reported surface markers rep-
resenting multi-potentiality include Stro-117, CD16618, CD10519,
CD49a20, and CD7321. Currently, for synovium-derived cells, little
information has been available on this issue in the literature;
a report demonstrated that CD9/CD90/CD166 triple-positive cells
have multipotency for mesenchymal differentiation22, while
another report demonstrated that CD105-positive synovial MSCs
have chondrogenic potential23. Nevertheless, there is still lack of
precise information on the distribution of the potential surface
markers in the synovial cells for chondrogenic differentiation, and
comparative results regarding chondrogenic capacities of the cells
sorted by each antigen.
In this study, we aimed to evaluate expression levels of nine
candidate surface markers for chondrogenic potential in human
synovial cells and sought to determine whether cell pellets posi-
tively sorted by each speciﬁc marker would have valuable chon-
drogenic potential.Materials and methods
Harvest of synovial tissue and isolation of synovium-derived cells
For this study, we used synovial tissues of knee joints in patients
with primary knee OA who underwent total knee arthroplasty
(TKA). The synovial tissues used in this study were obtained from
the suprapatellar pouch, medial and lateral gutters, and infrapa-
tellar fat pad areas during TKA. We excluded patients with the
following conditions: a diagnosis different from primary OA
including inﬂammatory arthritis (rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis), secondary arthritis related to
trauma and/or infection, alcoholism, and those who were chronic
steroid users.
After exclusion, we used 15 samples of synovial tissue from 15
patients. There were 13 female patients and two male patients. The
mean patient age (in years) was 69.8 [standard deviation (SD) 5.4],
and the mean body mass index was 28.7 kg/m2 (SD 3.2).
Harvested synovium was rinsed with Dulbecco’s phosphate-
buffered saline (DPBS, Gibco, Paisley, UK) supplemented with
antibioticeantimycotic solution. After ﬁnely mincing the synovial
tissues, they were digested with 0.2% collagenase (Sigma, Saint
Louis, MO) in low-glucose Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM, Gibco) containing 10% fetal bovine serum (FBS) for 3 h.
Cells were collected by centrifugation, washed twice, resuspended
in low-glucose DMEM supplemented with 10% FBS and antibiotics
(growth medium), plated at a density of 5  105 cells per 150 mm
culture dish (Nunc Inc., Naperville, IL), and allowed to attach for 3
days at 37C. The medium was replaced every 2e3 days (three
times per week). After 10e14 days of primary culture, when the
sparsely attached cells reached 75e90% conﬂuence, they were
washed with DPBS, and harvested by treatment with trypsine
ethylenediaminetetraacetic acid (EDTA). The cells at this stage
were designated as primary cells (Passage 0, P0).Flow cytometric analysis
We selected nine candidate surface markers based on previous
studies18e21,24: CD10, CD29, CD44, CD49a, CD73, CD90, CD105,
CD133, and CD166. The expression levels of the selected surface
markers in the synovial cells were evaluated at the isolation stage
and after cultivation (up to P1 or P2) using ﬂow cytometry (FCM).For the analyses, phycoerythrin (PE)-conjugated monoclonal
antibodies (BD Pharmingen, San Diego, CA) were used for examina-
tion of CD10, CD29, CD44, CD49a, CD73, CD90, and CD166. For the
examination of CD105 and CD133, unconjugated monoclonal anti-
bodies (BD Pharmingen) were used as primary antibodies, and then
ﬂuorescein isothiocyanate (FITC)-conjugated goat anti-mouse Ig
antibodies (BD Pharmingen) were used as secondary antibodies.
Brieﬂy, cellswerewashed twice in FCMbuffer consisting of 1%bovine
serum albumin and 0.1% sodium azide in PBS, followed by incubation
at 4Cwith the relevant antibodies for 20min. For the examination of
CD105 and CD133, the same procedure was repeated for the reaction
of FITC-conjugated secondary antibody. The cells were washed in
FCM buffer and suspended in 500 mL FCM buffer for ﬂuorescence
automated cell sorting (FACS) analysis. For each sample, data were
collected by analyzing 10,000 events on a FACScallibur (Becton
Dickinson, San Jose, CA) using Cell-Quest software.
Immunomagnetic cell separation/magnetic-activated cell sorting
(MACS)
For cell sorting, a MACS method (Miltenyi Biotec, Auburn, CA)
was used. Brieﬂy, isolated cells were counted and suspended to
a concentration of 107 cells per 100 mL FCM buffer, followed by
incubation at 4C with primary antibodies for 20 min. The used
primary antibodies were PE-conjugatedmonoclonal antibodies (BD
Pharmingen, San Diego, CA) for the CD10, CD29, CD44, CD49a,
CD73, CD90, and CD106 markers and unconjugated monoclonal
antibodies for CD105 and CD133 markers. Cells were washed,
resuspended at 107 cells per 80 mL in MACS buffer (PBS with 0.5%
BSA and 2 mM EDTA, pH 7.2), and incubated with 20 mL anti-PE Ig-
microbeads (for CD10, 29, 44, 49a, 73, 90, and 106, Miltenyi Biotec)
or anti-mouse Ig-microbeads (for CD105 and 133, Miltenyi Biotec)
for 15 min at 4C. The cells were washed and resuspended with
500 mL MACS buffer. After completion of the preparation, the cells
were separated using a magnetic column (LSþ, Miltenyi Biotec)
according to the manufacturer’s recommendation. Three different
experimental groups were developed for the same donors: the
presorting, positive sorting, and negative sorting groups. The pre-
sorting group was deﬁned as the cells before MACS, the positive
sorting group was deﬁned as cells captured in the magnetic
column. The negative sorting groupwas deﬁned as cells collected as
the column elution while the positive cells remained attached to
the column. To recover the positive cells, the column was removed
from the magnet, and the cells were ﬂushed out with MACS buffer.
After MACS, the cells of each group were counted, and the
proportions of target cell surface markers in each group were
assessed using FCM. We deﬁned the success of positive sorting as
>80% of the sorted cells expressed the target surface marker and
the success of negative sorting as<20% of the sorted cells expressed
the target marker (Fig. 1). We then prepared pellet cultures for the
sorted cells to evaluate chondrogenic potential to obtain both the
positive and negative groups from the same donor.
Chondrogenic differentiation
Chondrogenic differentiation in cell pellets was performed as
described previously25. Brieﬂy, 5  105 cells were centrifuged at
1500 rpm for 5 min in 15 mL polypropylene tubes and resuspended
in 500 mL chemically deﬁned chondrogenic medium. This medium
consisted of low-glucose DMEM supplemented with 1 mM pyru-
vate, 100 nM dexamethasone (Sigma), 40 mL/mL proline (Sigma),
100 mM ascorbate-2-phosphate (Sigma), 10 mL/mL insulin-trans-
ferrin-selenium (ITS) premix universal culture supplement (BD
Biosciences, Bedford, MA, USA) including 6.25 mg/mL insulin,
6.25 mg/mL transferrin, 6.25 mg/mL selenious acid, 5.35 mg/mL
Fig. 1. Example of immune-selection process of synovium-derived MSCs. After MACS, the cells of each group were counted, and the proportions of target cell surface markers in
each group were assessed using FCM. We deﬁned the success of positive sorting as >80% of the sorted cells expressed the target surface marker and the success of negative sorting
as <20% of the sorted cells expressed the target marker.
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transforming growth factor-b1 (TGF-b1; BioSource, Camarillo, CA).
The cell pellets were cultured at 37C with 5% CO2 for 21 days, and
the mediumwas changed every 2 days. Chondrogenic pellets were
harvested at 21 days for gene expression analysis, histological
evaluation, and glycosaminoglycan (GAG) quantiﬁcation11.
Analysis of chondrogenic potential by chondrogenic gene expression
First, quantitative assessment of the mRNA expression of type II
collagen, which is a speciﬁc and major component of articular
cartilage, was performed by real-time polymerase chain reaction
(PCR) using TaqMan probes [ABI PRISM 7300 Sequence Detection
System (Applied Biosystems, Foster City, CA)]. In the analysis, we
used 10 pellets per each group in a subject, and were able to
completely assess the mRNA expression levels of type II collagen of
all the cell pellet groups in nine subjects. The PCR primers and
TaqMan probe were designed by Assays-by-Design SM service
(Applied Biosystems) as follows: type II collagen 50-CCAACGTCCA
GATGACCTT-30 (forward) and 50-CTGCTTCGTCCAGATAGGCAAT-30
(reverse), and TaqMan TAMRA probe 50-[FAM] CTG TCC ACG GAA
GGC TCC CAG AAC A [TAMRA]-30. The content of cDNA samples wasTable I
The expression of nine surface markers from digested cells and after cultivation (up to P
Surface markers Digested cells (n ¼ 15) P0 (n ¼
CD10 16.9 (14.1, 19.8) 59.9 (5
CD29 83.7 (81.8, 85.5) 99.0 (9
CD44 87.6 (82.0, 93.2) 99.4 (9
CD49a 25.6 (22.0, 29.1) 24.0 (1
CD73 77.1 (73.2, 81.0) 98.9 (9
CD90 62.3 (57.1, 67.4) 93.9 (9
CD105 27.6 (19.8, 35.5) 70.4 (5
CD133 0.4 (0.3, 0.5) 0.6 (0
CD166 7.1 (4.1, 10.2) 22.3 (1
Abbreviation: P, passage.
* Data are presented as the mean and 95% conﬁdence interval in parentheses obtainenormalized by subtracting the number of copies of the endogenous
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reference
gene from the number of copies of the target gene (DCt ¼ Ct of
target gene  Ct of GAPDH). Expression of the speciﬁc gene was
calculated using the formula 2(DCt).
Then, the chondrogenic differentiation potential of the cells
was studied by reverse transcription PCR (RT-PCR) analysis of the
expression of two speciﬁc genes representing chondrogenic
differentiation, including type II collagen and aggrecan. For this
purpose, total RNA was extracted using TRIzol reagent (Life
Technologies) according to the manufacturer’s recommendation.
An RNA isolate from each subpopulation was then used as
a template for cDNA synthesis, which was prepared using Molo-
ney murine leukemia virus (MMLV) reverse transcriptase (Invi-
trogen). The expression of various transcripts was assessed by PCR
ampliﬁcation. Primers sets used in this study were as follows: (1)
type II collagen 50-CTGCTCGTCGCCGCTGTCCTT-30 (forward)
and 50-AAGGGTCCCAGGTTCTCCATC-30 (reverse), (2) aggrecan 50-
TGAGGAGGGCTGGAACAAGTACC-30 (forward) and 50-GGAGGTGG
TAATTGCAGGGAACA-30 (reverse), and (3) GAPDH 50-ATTGTTGC
CATCAATGACCC-30 (forward) and 50-AGTAGAGGCAGGGATGA
TGTT-30 (reverse). Following ampliﬁcation, each reaction mixture1 or 2)*
15) P1 (n ¼ 15) P2 (n ¼ 12)
5.1, 64.6) 71.9 (66.7, 77.2) 89.8 (88.4, 91.2)
8.7, 99.3) 99.2 (99.0, 99.5) e
9.3, 99.5) 99.4 (99.2, 99.5) e
6.9, 31.2) 26.3 (20.6, 31.9) 29.7 (22.0, 37.4)
8.4, 99.4) 99.5 (99.4, 99.6) e
1.5, 96.3) 99.2 (99.0, 99.5) e
8.8, 81.9) 86.9 (81.9, 91.9) 91.2 (89.2, 93.2)
.5, 0.7) 0.5 (0.4, 0.6) e
6.5, 28.1) 32.7 (26.3, 39.1) 42.5 (37.7, 47.3)
d from the number of donors indicated in parentheses.
Fig. 2. Chart showing the relative gene expression levels of type II collagen of all the positive and negative cell pellets in nine subjects. The black dot and bar represent relative level
of type II collagen mRNA expression of each marker-positive cell pellets and the adjacent white dot and bar represent that of the corresponding marker-negative cell pellets. Only
the pellets of CD105- and CD166-positive cells had signiﬁcantly better mRNA expression levels of type II collagen than the corresponding negative cell pellets.
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bromide staining. RNA integrity was assessed by the expression of
GAPDH.
Analysis of chondrogenic potential by histological evaluation
For histological evaluation, pellets were harvested and ﬁxed in
4% paraformaldehyde for 4 h at room temperature. The ﬁxed pellet
was placed into Tissue-Tek embedding medium (Sakura Finetek,
Torrance, CA) and frozen at 70C. Sections of 5 mm thickness were
cut on a cryostat at 20C and mounted onto slides. Sections were
air dried and immediately ﬁxed in absolute acetone at 20C for
15 min.
For immunoﬂuorescence, the specimens were digested for
30 min with 50 U/mL chondroitinase ABC (Sigma) in 100 mM Tris-
acetate. Non-speciﬁc binding of antibody was eliminated by incu-
bating the specimens with blocking solution (Zymed Laboratories
Inc., San Francisco, CA) for 10 min at room temperature. Mouse
monoclonal anti-collagen 2Ab (NeoMarkers, Fremont, CA) was
applied for 1 h at room temperature followed by incubation with
2 g/mL of FITC-goat anti-mouse Ig Ab for 1 h. Finally, slides were
washed three times in PBS and mounted using mounting medium.Fig. 3. Figure showing gross features (the ruler is graduated in millimeters) and type II
collagen and aggrecan gene expression levels of the CD105-positive [105(þ)] and
negative [105()] pellets. Without TGF-b [TGF()], expression levels of those chon-
drogenic genes in both the CD105-positive and negative pellets were very low, while,
with TGF-b [TGF(þ)], those expression levels were much higher in the CD105-positive
pellets than in the CD105-negative pellets.Staining was observed using a confocal microscope (LSM 510, Carl
Zeiss, Germany).
For immunohistochemistry, endogenous peroxidase activity
was blocked by 8e10 h incubation in 0.3% H2O2 in methanol.
Sections were then pretreatedwith 0.2% hyaluronidase in 0.1 M PBS
for 30min at 37C. Residual enzymewas removedwith three 5-min
washes with PBS, and blocking solution was placed on the section
for 30 min at room temperature. Mouse monoclonal anti-collagen
2Ab (NeoMarkers) was placed on the sections for 16e24 h at 4C.
After washing with PBS to remove residual primary antibody,
reactivity was detected using biotinylated secondary antibody and
streptavidineperoxidase. Peroxidase activity was visualized using
diaminobenzidine as a substrate. The sections were counterstained
with hematoxylin.
Analysis of chondrogenic potentials by GAG evaluation
Total GAG levels in the medium and cell pellet were determined
using the dimethylmethylene blue (DMB) assay26. In the analysis,
we used ﬁve pellets per each group in a subject, and were able to
completely assess the GAG levels of positive sorting and negative
sorting cell pellet groups in nine subjects. Samples were digested in
papain buffer solution (100 mg/mL papain in 5 mM EDTA, 0.1 M
sodium formate, and 5mM L-cysteine, pH 3.0) for 16 h at 65C. After
centrifugation for 5 min at 6000 rpm, a 50 mL aliquot of the upper
layer was plated in 96-well plates, and 250 mL DMB dye solution
was added. DMB dye solution was prepared with 16 mg DMB dis-
solved in 5 mL 95% ethanol. The dissolved dye was diluted in 3 mLFig. 4. Figure showing type II collagen and aggrecan gene expression of the presorted
cell pellets (Pre), CD166-positive [166(þ)] and negative [166()] pellets. Compared to
the CD166-negative cell pellets, CD166-positive cell pellets showed higher expression
of those chondrogenic genes.
Fig. 5. Chart showing the relative protein levels of type II collagen synthesis of all the
positive and negative cell pellets. The white bar and the gray bar represent relative
protein levels of type II collagen of each marker-positive and negative cell pellets,
which were examined by ELISA. Compared to the CD105- and CD166-negative cell
pellets, CD105- and CD166-positive cell pellets showed higher protein levels of type II
collagen.
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with 1 L distilled water, and concentrated formic acid was used to
adjust the pH of the solution. GAG levels were determined using an
enzyme-linked immunosorbent assay (ELISA) reader from the ratio
of absorbance at 530 and 590 nM. Chondroitin-6-sulfate was dis-
solved to be used as the standard, and the GAG levels were then
normalized to total cellular DNA, which was measured by the
Indole assay. Brieﬂy, 100 mL 1 N NaOH and 100 mL Indole reagent
was added to the cell pellets, heated for 10 min at 100C, and plated
in 96-well plates. Total DNA levels were quantiﬁed with an ELISA
reader at 490 nm.Fig. 6. Fluorescent immunohistochemistry analysis of type II collagen in CD105-positive [CD
enriched cell pellet showed higher level of type II collagen synthesis relative to the CD105 d
staining for cell nuclei (Original magniﬁcation 100).Analysis of chondrogenic potentials by ELISA
Pellets were digested with pepsin solution (2 mg/mL pepsin in
0.05 M acetic acid, 0.5 M sodium chloride) for 72 h at 4C, followed
by 24 h of further digestion at 4C in pancreatic elastase solution
(1 mg/mL dissolved in 1 TBS, pH 7.8e8.0). The collagen type II
content was measured by type II collagen detection ELISA (MD
Biosciences, St. Paul, MN, USA) according to manufacturer’s
instructions.
Statistical analyses
The expression levels of the nine surface markers in the synovial
cells at the isolation stage and after cultivation (up to P1 or P2) were
documented. Comparative analyses of the relative levels of the type
II collagen mRNA expression between the positive sorting and
negative sorting groups were carried out using theWilcoxon signed
ranks test. In addition, comparative analyses of the total GAG levels
in the medium and cell pellet between the positive sorting and
negative sorting groups were carried out using theWilcoxon signed
ranks test as well.
Statistical analysis was performed using SPSS for Windows
(Version 17.0, SPSS Inc, Chicago, IL), and P values of <0.05 were
considered signiﬁcant.
Results
Surface marker proﬁle and immunoselection of synovium-derived
cells
The surface markers CD29, CD44, CD73, and CD90 were
expressed on themajority of synovial cells at the isolation stage and
almost all cells at P0 and P1. CD133 was rarely expressed at any105(þ)] and negative [CD105()] cell pellets. After chondrogenic differentiation, CD105
epleted cell pellet. Green, type II collagen; blue, 4',6-diamidino-2-phenylindole (DAPI)
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the isolation stage on average, but this expression increased after
cell passages. The expression of CD10 and CD105 also increased
after cell passages, while the expression of CD49a did not (Table I).
Based on the expression levels of cell surface markers, we per-
formed surface marker-based cell sorting by MACS at three
different times as follows: synovial cells for CD29, 44, 73, and 90,
which were expressed in almost all cells even at the P0 stage, were
sorted immediately after isolations, while cells for CD10, 49a, and
105 were sorted after primary cultivation (P0). Cells for CD166,
which was not sufﬁciently expressed even after P0, were sorted
after secondary cultivation (P1). We could not obtain cells posi-
tively sorted for CD133, which was expressed in less than 1% of cells
even at P1, with our deﬁnition of positive expression (>80% of the
sorted cells expressed the target surface marker) in all samples.
Thus, we did not perform pellet culture for CD133. In addition, as
synovial cells for the surface markers CD29, 44, 73, and 90 should
be sorted immediately after isolation, the numbers of sorted cells,Fig. 7. Enzymatic immunohistochemistry analysis of type II collagen in CD105-positive [CD1
enriched cell pellet showed higher level of type II collagen synthesis relative to the CD105particularly negatively-sorted cells, were not sufﬁcient for pellet
culture. Thus, we were supposed to perform pellet cultures after
primary cultivation of the positively- and negatively-sorted syno-
vial cells for CD29, 44, 73, and 90, while we could perform pellet
cultures of synovial cells for the other markers except CD133
immediately after sorting.
Chondrogenic differentiation of immunoselected synovial cells
Real-time PCR results revealed that the pellets of CD105- and
CD166-positive cells had signiﬁcantly better mRNA expression of
type II collagen, suggesting better chondrogenic differentiation,
than CD105- and 166-negative pellets, respectively. However, no
signiﬁcant differences of expression were found between the
positive and negative cell pellets of CD44, 73, 90, 29, 10, or 49a,
which were previously reported as speciﬁc markers for MSCs
(Fig. 2). Whenwe set the levels of type II collagenmRNA expression
in the presorted cell pellets as 1, the relative average expression05(þ)] and negative [CD105()] cell pellets. After chondrogenic differentiation, CD105
depleted cell pellet (Original magniﬁcation 100).
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were 0.35 and 1.48, respectively (P ¼ 0.008). Similarly, relative
average expression ratios of type II collagen in CD166-negative and
positive pellets were 0.77 and 2.14, respectively (P ¼ 0.008).
Although both the CD105-positive and negative pellets rarely
expressed two chondrogenic genes (type II collagen and aggrecan)
without TGF-b, those expression levels were higher in the CD105-
positive pellets than in the CD105-negative pellets with TGF-
b (Fig. 3). Similarly, CD166-positive pellets showed higher expression
of type II collagen and aggrecan than CD166-negative pellets with
TGF-b (Fig. 4). Accordingly, the content of type II collagen by ELISA
is shown in Fig. 5. High levels of type II collagen were detected in
the CD105-positive pellets than in the CD105-negative pellets. Also,
CD166-positive pellets showed higher levels of type II collagen
synthesis than CD166-negative cell pellets (Fig. 5).
Immunoﬂuorescence and immunohistochemical staining of
type II collagen showed that the CD105-positive cell pellets had
higher levels of type II collagen synthesis than CD105-negative cell
pellets and well-formed matrices (Figs. 6 and 7). Likewise, CD166-
positive cell pellets showed higher levels of type II collagen
synthesis than CD166-negative cell pellets and well-formed
matrices (Figs. 8 and 9). However, synovium cell pellets sorted
with CD44, 73, 90, 29, 10, and 49a had no signiﬁcant differences in
the levels of type II collagen synthesis between positive and
negative pellets.
In terms of GAG synthesis by isolated cells cultured in pellets,
CD105- and CD166-positive cell pellets exhibited signiﬁcantly
greater GAG synthesis than CD105- and CD166-negative cell
pellets, respectively (P ¼ 0.008 and 0.011, respectively). No signif-
icant differences were observed between positive pellets and
negative pellets of the following surface antigens: CD10, CD29,
CD44, CD49a, CD73, and CD90 (Fig. 10).Fig. 8. Fluorescent immunohistochemistry analysis of type II collagen in CD166-positive [CD1
enriched cell pellet showed higher level of type II collagen synthesis relative to the CD166
magniﬁcation 100).Discussion
In this study, we sought to identify the expression levels of nine
cell surface markers which were previously reported as markers of
MSCs in synovium-derived cells from elderly knee OA patients. We
also examined whether each marker could represent chondrogenic
differentiation potential by comparison of the differentiation levels
between positively- and negatively-sorted cell pellets of each
surface marker. Our results suggest that CD105 and CD166 would
be valuable markers for chondrogenic differentiation using human
synovium-derived cells.
Adult MSCs have received increasing attention as cell sources
for regeneration of the bone and joint systems6e8. Nevertheless,
despite several merits, adult MSCs have critical limitations in their
clinical applications, including heterogeneous features of har-
vested cells and scarcity of multipotent cells among them. In
efforts to solve these problems, a number of investigators have
sought to identify markers representing multipotency of adult
MSCs.
Since late 1990, several reports have proposed surface markers
that might represent MSC multipotency. Bone marrow-derived
MSCs can generate colony forming units-ﬁbroblast (CFU-F) in
culture, and it was reported that the CFU-F colonies express speciﬁc
membrane antigens, such as Thy-1 (CD90), CD29, CD49a, and CD10.
Thus, it was suggested that these surface markers would be speciﬁc
markers that deﬁned stem cells20,27. In addition, CD73, which was
reported to an antigen containing SH3 and SH4 epitopes21, and
CD44, which was reported to have a role in MSC cell migration,
were suggested as candidate markers of adult MSCs28. However,
our ﬁndings questioned the value of those surface antigens as
markers for sorting MSCs, in particular for chondrogenic differen-
tiation, in human synovium-derived cells. Our FCM result revealed66(þ)] and negative [CD166()] cell pellets. After chondrogenic differentiation, CD166-
depleted cell pellet. Green, type II collagen; blue, DAPI staining for cell nuclei (Original
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of human synovial cells even at the isolation stage. This result
suggests that even if these surface markers have roles in adult
MSCs, the markers would be common antigens over all cells from
human synovial tissue and thus would be inappropriate markers
for speciﬁcally sorting MSCs. We conﬁrmed such a speculation by
comparing the chondrogenic differentiation potential between cell
pellets negatively and positively sorted with these surface markers,
which showed no signiﬁcant differences between them. In addi-
tion, CD10 and CD49a, which were relatively less expressed at the
isolation stage, also failed to showa value asMSC targetmarkers for
chondrogenic differentiation in this study.
Our ﬁnding suggests that CD105 and CD166 would be valuable
markers for sorting MSCs for chondrogenic differentiation in
human synovium-derived cells. We found that the proportion of
human synovial cells expressing CD105 and CD166 was relatively
low at the isolation stage but increased with serial passaging. In
addition, cell pellets positively sorted with CD105 and CD166
showed better chondrogenic potentials in terms of type II collagenFig. 9. Enzymatic immunohistochemistry analysis of type II collagen in CD166-positive [CD1
enriched cell pellet showed higher level of type II collagen synthesis relative to the CD166gene expression, histological cartilage matrix formation, and GAG
expression than corresponding marker-negative cell pellets. The
CD105 (endoglin) antigen is a receptor of TGF-b1 and TGF-b3,
which have pivotal roles in chondrogenesis25,29e31. Thus, theo-
retically, it can be a marker for MSCs for chondrogenesis. Barry
et al. reported that CD105 represented SH2 antibody which is an
essential part of chondrogenic differentiation and interaction
among the MSCs18. Moreover, it was found that bone marrow-
derived CD105-positive cells expressed type II collagen mRNA
and secreted type II collagen when cultured in alginate beads19.
Our data also identiﬁed the potential for chondrogenic differen-
tiation with subpopulations expressing CD105 in synovial MSCs.
CD166 (activated leukocyte cell adhesion molecule e ALCAM) is
a member of the immunoglobulin superfamily that is involved
with hemophilic adhesion, as well as CD6 binding32. ALCAM-
mediated hemophilic cell adhesion is tightly regulated through
the actin cytoskeleton by the formation of clusters of molecules at
the cell surface33. CD166 is also reported to be expressed on
MSCs34.66(þ)] and negative [CD166()] cell pellets. After chondrogenic differentiation, CD166-
depleted cell pellet (Original magniﬁcation 100).
Fig. 10. Chart showing the relative levels of GAG synthesis of all the positive cell pellets in nine subjects. The black dot and bar represent levels of GAG synthesis of each marker-
positive cell pellets relative to those of corresponding marker-negative cell pellets. Only CD105- and CD166-positive cell pellets exhibited signiﬁcantly greater GAG synthesis than
the corresponding negative cell pellets.
C.B. Chang et al. / Osteoarthritis and Cartilage 21 (2013) 190e199198In conclusion, our study suggests that CD105 and CD166 would
be valuable surface markers associated with chondrogenic poten-
tial, and thus CD105- and CD166-enriched cells derived from
human synovium would be practical and valuable sources for
cartilage regeneration.
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